Connecting to lifecycle management program information
Novartis Oncology is conducting global development initiatives for key molecules encompassing a broad range of malignancies. Open partnerships within the oncology care community enable us to conduct high-quality clinical trials with competitive timelines and aid in the discovery of new uses of our medicines to benefit patients.
PRI3M (Pioneering Research of PI3K inhibitors in Malignancies) is a program of clinical research sponsored by Novartis.
Here you will find information about the PI3K/Akt/mTOR pathway and the clinical trials with the Novartis PI3K inhibitor buparlisib (BKM120), which are currently enrolling patients with metastatic breast cancer and head and neck squamous cell cancer (HNSCC.)
ClinicalTrials.gov is a website service provided by the United States National Institutes of Health (NIH). The NIH, through its National Library of Medicine, has developed this website in collaboration with the Food and Drug Administration (FDA), as a result of the FDA Modernization Act, which was passed into law in November 1997.
This service is provided by the IFPMA, on behalf of its Member Companies and Associations. The portal has been designed as a single entry allowing you to search for comprehensive information on ongoing clinical trials (registry) or results of completed trials (database) conducted by the innovative pharmaceutical industry.
All Compounds are either investigational or studied in new indications. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.
The search results, details, and descriptions of clinical trials viewed herein are supplied by ClinicalTrials.gov and EUtrialregistry.com. This information is maintained by a third party over whom Novartis Pharmaceuticals Corporation has no control. As such, Novartis Pharmaceuticals Corporation does not guarantee the accuracy, completeness, adequacy, or any other aspect of the information contained on this site.